Corporate Overview

TCR² is an innovative immunotherapy company developing the next generation of T cell therapies for patients suffering from cancer. Our proprietary TRuC™ (TCR Fusion Construct) T cells – a novel T cell therapy platform – reprogram the natural T cell receptor complex to recognize and kill cancer cells using the full power of T cell signaling pathways independent of HLA.

Stock Information

Exchange :
Today's Open
Previous Close

Stock Chart

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Corporate Presentation